Form 4: Cassava Sciences Executive Granted Stock Options

Robert Christopher Cook, Chief Operating & Legal Officer of Cassava Sciences, was granted stock options for 100,000 shares on April 17, 2025.

Summary

• Robert Christopher Cook, the Chief Operating & Legal Officer of Cassava Sciences, was granted stock options on April 17, 2025.
• The options are for 100,000 shares of Cassava Sciences common stock.
• The exercise price of the options is $1.44 per share.
• The options vest in four equal annual installments, with the first 25% vesting on April 17, 2026.
• The options expire on April 17, 2035.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of stock option grants, which is generally viewed neutrally to positively as it incentivizes management. The sentiment is slightly positive as it indicates confidence in the company's future.

Positives

• The granting of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize stock options to incentivize their executives.
• The vesting schedule of four years is typical for such grants, aligning with industry norms.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns management's interests with increasing shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, Cassava Sciences, executive compensation, Form 4, SAVA, Robert Christopher Cook, Chief Operating & Legal Officer